A research conducted at the International Space Station has yielded early insights regarding the structure and size of particles best suited for the development of a cancer medicine.
In collaboration with scientists at Merck, protein crystal growth research in space gave input regarding the structure and size of particles ideal for developing a new formulation of the company's cancer medicine pembrolizumab for subcutaneous injection.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Joji Xavier
For comments and feedback: contact editorial@rttnews.com